Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Extends Exchange Offer for Helomics Notes and Warrants
MINNEAPOLIS , March 14, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”) today announced the extension of its previously announced offer (the “Exchange Offer”) to holders of certain promissory notes (the “Helomics Notes Payable”) of Helomics Holding
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Captures Market Share in Saudi Arabia Via New Orders While Disposable Sales Show Significant Year-Over-Year Increase
Company Concluded 2018 With 38 Percent Increase in STREAMWAY System Disposables MINNEAPOLIS , March 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, has entered the African continent, further
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Pricing of Public Offering of Up to $1.26 Million of Units
MINNEAPOLIS , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced the pricing of its previously announced public offering of its common stock and warrants to purchase common stock, with anticipated gross proceeds of up to $1.26
View HTML
Toggle Summary Precision Therapeutics Inc. Announces Proposed Public Offering of Securities
MINNEAPOLIS , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no
View HTML
Toggle Summary Precision Therapeutics Inc. is Excited to Announce a Special Meeting of Stockholders and Commencement of Registered Exchange Offer
MINNEAPOLIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the proposed business
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria
MINNEAPOLIS , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked  STREAMWAY ® System  for automated, direct-to-drain medical fluid disposal, has received
View HTML
Toggle Summary Precision Therapeutics’ TumorGenesis Division Isolates Discovery Biomarkers for Thyroid Cancer Cell Types, Initiating Its Proprietary Process for New Drug Development Via Patient-Derived Tumor Models
MINNEAPOLIS , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers.  The company will utilize this discovery to
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Widens Global Reach Through New Taiwanese Distribution Agreement with Winner Scientific
Company Further Expands Global Outreach Through Exhibition at Arab Health Show in Dubai MINNEAPOLIS , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and
View HTML
Toggle Summary Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
MINNEAPOLIS , Jan. 18, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its chief executive officer and director, Carl Schwartz , has made an additional investment of $1,000,000 in the Company, effective January 8, 2019 .
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Significantly Expands Footprint in New England With Sale of Six STREAMWAY Systems to Yale University Ambulatory Outpatient Surgical Center
Large Sale to Prestigious Health System Further Validates STREAMLINE Utility MINNEAPOLIS , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked 
View HTML